Aeolus initiates drug study for radiation exposure
Aeolus Pharmaceuticals has initiated a second study of its lead drug, AEOL 10150, funded by the National Institute of Allergy and Infectious Diseases radiation/nuclear medical countermeasures development program as a countermeasure for radiation exposure to the gastrointestinal (GI) tract.
The study is designed to test the efficacy of AEOL 10150, as measured by survival advantage, as a treatment for damage to the GI tract due to exposure to radiation.
AEOL 10150 is a small molecule that catalytically consumes reactive oxygen and nitrogen species (free radicals), said the Mission Viejo, Calif.-based Aeolus.
Prior study showed regeneration of gastro-intestinal stem cells, reduction in severity and duration of diarrhea and improved survival in animals receiving AEOL 10150 after exposure to 15 Gy of radiation, according to Aeolus.
The study is designed to test the efficacy of AEOL 10150, as measured by survival advantage, as a treatment for damage to the GI tract due to exposure to radiation.
AEOL 10150 is a small molecule that catalytically consumes reactive oxygen and nitrogen species (free radicals), said the Mission Viejo, Calif.-based Aeolus.
Prior study showed regeneration of gastro-intestinal stem cells, reduction in severity and duration of diarrhea and improved survival in animals receiving AEOL 10150 after exposure to 15 Gy of radiation, according to Aeolus.